Effect of glucagon-like peptide-1 for the treatment of diabetes mellitus

Abstract

Abstract: Glucagon-like peptide-1(GLP-1) is one of the key incretins secreted by L-cell in intestine. The bioactivities of GLP-1 in vivo includes the enhancement of glucose-dependent insulin secretion and insulin dilivery, suppression of glucagon secretion, promotion of β-cell proliferation and differentiation, inhibition of gastric emptying and appetite. Studies demonstrated that GLP-1 might be used as a new drug for the treatment of diabetes mellitus and obesity in future. However, GLP-1 is quickly degradated by DPP-IV in vivo and its plasma half-life is short, thus the studies of DPP-IV inhibitors are another aspect for durg development. At present, several GLP-1 derivates and DPP-Ⅳ inhibitors may have important application perspective as new therapeutic agents in the treatment of diabetes mellitus and obesity.

Key words: glucagon-like peptide-1, diabetes mellitus, derivate

CLC Number:

R587.1

LU Shou-si, YU Yun-li, LIU Xiao-dong, YANG Yong-ge. Effect of glucagon-like peptide-1 for the treatment of diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(11): 1298-1303.

References

[1] Doyle ME, Egan JM. Mechanisms of action of glucagonlike peptide 1 in the pancreas[J]. Pharmacol Ther, 2007, 113(3): 546-593.
[2] Rowland KJ, Brubaker PL.Life in the crypt: a role for glucagon-like peptide-2[J]. Mol Cell Endocrinol, 2008, 288(12): 63-70.
[3] Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis[J]. Mol Endocrinol, 2003, 17(2): 161-171.
[4] Brubaker PL, Drucker DJ.Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system[J]. Endocrinology, 2004, 145(6): 2653-2659.
[5] Tanya H, Adriano M, Flock G, et al. Extra-pancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure[J]. Clin Invest, 2007, 117(1): 143-152.
[6] Vahl TP, Tauchi M, Durler TS, et al. Glucagon-like peptide- 1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose to lerance in rats[J]. Endocrinology, 2007, 148(10): 4965-4973.
[7] Aaboe K, Krarup T, Madsbad S, et al. GLP-1:physiological effects and potential therapeutic applications[J]. Diabetes ObesMetab, 2008, 22: [Epub ahead of print].
[8] Blundell JE, Levin F, King NA, et al. Overconsumption and obesity: peptides and susceptibility to weight gain[J]. Regul Pept, 2008, 149(1/3): 32-38.
[9] Pörksen S, Nielsen LB, Kaas A, et al. Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes[J]. J Clin Endocrinol Metab, 2007, 92(8): 2910-2916.
[10] Fung M, Thompson D, Shapiro RJ, et al. Effect of glucagon- like peptide-1(7-37) on beta-cell function after islet transplantation in type 1 diabetes[J]. Diabetes Res Clin Pract, 2006, 74(2): 189-193.
[11] Wideman RD, Yu IL, Webber TD, et al. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1)[J]. Proc Natl Acad Sci USA, 2006, 103(36): 13468-13473.
[12] Pratley RE.Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes[J]. Medscape JMed, 2008, 10(7): 171-175.
[13] Drucker DJ.Glucagon-like peptide-1 and the islet betacell: augmentation of cell proliferation and inhibition of apoptosis[J]. Endocrinology, 2003, 144(12): 5145-5148.
[14] Pi-Sunyer FX.The effects of pharmacologic agents for type 2 diabetes mellitus on body weight[J]. Postgrad Med, 2008, 120(2): 5-17.
[15] Aronne LJ, Thornton-Jones ZD.New targets for obesity pharmacotherapy[J]. Clin Pharmacol Ther, 2007, 81(5): 748-752.
[16] Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon- like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans[J]. Gut, 2006, 55(2): 243-251.
[17] Chiu KC, Lee NP, Cohan P, et al. Beta cell function declines with age in glucose tolerant Caucasians[J]. Clin Endocrinol(Oxf), 2000, 53(5): 569-575.
[18] Meneilly GS, Greig N, Tildesley H, et al. Effects of 3 months of continuous subcutaneous administration of glucagon- like peptide 1 in elderly patients with type 2 diabetes[J]. Diabetes Care, 2003, 26(10): 2835-2841.
[19] Zander M, Madsbad S, Medsen JL, et al. Effect of 6- week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and-cell function in type 2 diabetes: a parallel-group study[J]. Lancet, 2002, 359(9309): 824-830.
[20] Shinde J, Taldone T.Alpha-glucosidase inhibitory activity of Syzygium cumini (Linn.) Skeels seed kernel in vitro and in Goto-Kakizaki (GK) rats[J]. Carbohydr Res, 2008, 343(7): 1278-1281.
[21] Liu L, Deng YX, Liu XD, et al. Berberine attenuates intestinal disaccharidases in streptozotocin-induced diabetic rats[J]. Pharmazie, 2008, 63(5): 384-388.
[22] Delzenne NM, Cani PD, Neyrinck AM. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: experimental data[J]. J Nutr, 2007, 137(11 Suppl): 2547S-2551S.
[23] Cani PD, Hoste S, Guiot Y, et al. Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats[J]. Bri J Nutr, 2007, 98(1): 32-37.
[24] Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride,placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met) [J]. Diabetes Care, 2008, 17:[Epub ahead of print].
[25] Duffy NA.Effects of anti-diabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1[J]. Eur J Pharmacol, 2007, 568(1/3): 278-286.
[26] Yin DF, Wu C Lu Y, et al. Long-acting injectable microspheres of Glucagon-like peptide-1[J]. Yao Xue Xue Bao, 2006, 41(7): 603-607.